{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:02:44Z","timestamp":1777053764184,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semerg.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T13:40:08Z","timestamp":1520862008000},"page":"472-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Persistencia al tratamiento y uso de recursos con corticosteroides y agonistas \u03b2-adren\u00e9rgicos de larga duraci\u00f3n inhalados a dosis fijas para el tratamiento del asma: estudio retrospectivo de base poblacional"],"prefix":"10.1016","volume":"44","author":[{"given":"A.","family":"Sicras-Mainar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Traseira-Lugilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Fern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Navarro-Artieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2018.01.011_bib0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7196\/SAMJ.6526","article-title":"Guideline for the management of acute asthma in adults: 2013 update","volume":"103","author":"Lalloo","year":"2012","journal-title":"S Afr Med J."},{"issue":"Suppl 7","key":"10.1016\/j.semerg.2018.01.011_bib0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0300-2896(10)70041-7","article-title":"ALERTA 2 guidelines Latin America and Spain: Recommendations for the prevention and treatment of asmatic exacerbations","volume":"46","author":"Rodrigo","year":"2010","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2018.01.011_bib0180","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2017 GINA Report 2017 Update. [consultado 22 Jul 2017]. Disponible en: http:\/\/www.ginasthma.org"},{"key":"10.1016\/j.semerg.2018.01.011_bib0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.arbres.2014.08.010","article-title":"Prevalence of work-related asthma and its impact in primary health care","volume":"51","author":"Vila-Rigat","year":"2015","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2018.01.011_bib0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/17476348.2016.1114417","article-title":"Is asthma prevalence still increasing?","volume":"10","author":"Lundb\u00e4ck","year":"2016","journal-title":"Expert Rev Respir Med."},{"key":"10.1016\/j.semerg.2018.01.011_bib0195","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/all.12368","article-title":"The risk of asthma exacerbation after reducing inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials","volume":"69","author":"Hagan","year":"2014","journal-title":"Allergy."},{"key":"10.1016\/j.semerg.2018.01.011_bib0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.anai.2011.12.001","article-title":"Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations","volume":"108","author":"Zeiger","year":"2012","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.semerg.2018.01.011_bib0205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1183\/09031936.00172114","article-title":"Asthma inhaler adherence determinants in adults: Systematic review of observational data","volume":"45","author":"Dima","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.semerg.2018.01.011_bib0210","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00075614","article-title":"Medication adherence and the risk of severe asthma exacerbations: A systematic review","volume":"45","author":"Engelkes","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.semerg.2018.01.011_bib0215","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","article-title":"Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD","volume":"107","author":"M\u00e4kel\u00e4","year":"2013","journal-title":"Respir Med."},{"key":"10.1016\/j.semerg.2018.01.011_bib0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/02770900903497196","article-title":"Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population","volume":"47","author":"Mattke","year":"2010","journal-title":"J Asthma."},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2018.01.011_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1138-3593(16)30132-0","article-title":"Fixed-dose combination fluticasone propionate\/formoterol for the treatment of asthma: A review of its pharmacology, efficacy and tolerability","volume":"42","author":"Quintano Jim\u00e9nez","year":"2016","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2018.01.011_bib0230","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/jamp.2015.1255","article-title":"Long-term fluticasone propionate\/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations","volume":"29","author":"Papi","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"10.1016\/j.semerg.2018.01.011_bib0235","series-title":"The International Classification of Primary Care in the European Community. With a multi-language layer.","year":"1993"},{"key":"10.1016\/j.semerg.2018.01.011_bib0240","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"10.1016\/j.semerg.2018.01.011_bib0245","first-page":"308","article-title":"Adjusted clinicals groups: A patient classification system through risk adjustment","volume":"30","author":"Sicras-Mainar","year":"2013","journal-title":"Rev Peru Med Exp Salud Publica."},{"key":"10.1016\/j.semerg.2018.01.011_bib0250","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization [consultado 10 nov 2015]. Disponible en: http:\/\/www.who.int\/classifications \/atcddd\/en\/"},{"key":"10.1016\/j.semerg.2018.01.011_bib0255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.semerg.2018.01.011_bib0260","unstructured":"Instituto Nacional de Estad\u00edstica 2013. Encuesta de costes laborales del a\u00f1o 2013. [consultado 22 Jul 2017]. Disponible en: http:\/\/www.ine.es\/infoine"},{"key":"10.1016\/j.semerg.2018.01.011_bib0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5414\/CP201665","article-title":"A retrospective database analysis on persistence with inhaled corticosteroid therapy: Comparison of two dry powder inhalers during asthma treatment in Germany","volume":"50","author":"Voshaar","year":"2012","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1016\/j.semerg.2018.01.011_bib0270","article-title":"Asthma and adherence to inhaled corticosteroids: Current status and future perspectives","author":"B\u00e5rnes","year":"2014","journal-title":"Respir Care."},{"key":"10.1016\/j.semerg.2018.01.011_bib0275","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4104\/pcrj.2010.00061","article-title":"Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK","volume":"20","author":"Zhang","year":"2011","journal-title":"Prim Care Respir J."},{"key":"10.1016\/j.semerg.2018.01.011_bib0280","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rmed.2017.08.017","article-title":"Real-life effectiveness of asthma treatment with a fixed-dose fluticasone\/formoterol pressurised metered-dose inhaler. Results from a non-interventional study","volume":"131","author":"Schmidt","year":"2017","journal-title":"Respir Med."},{"key":"10.1016\/j.semerg.2018.01.011_bib0285","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaip.2017.02.006","article-title":"A randomized pragmatic trial of changing to and stepping down fluticasone\/formoterol in asthma","volume":"5","author":"Usmani","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.semerg.2018.01.011_bib0290","first-page":"CD005533","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","author":"Ducharme","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.semerg.2018.01.011_bib0295","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semerg.2018.01.011_bib0300","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rmr.2010.11.001","article-title":"The costs of asthma in France and the economic implications of its level of control","volume":"28","author":"Gadenne","year":"2011","journal-title":"Rev Mal Respir."},{"key":"10.1016\/j.semerg.2018.01.011_bib0305","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00130832-200406000-00009","article-title":"Medication non-adherence and asthma treatment cost","volume":"4","author":"Bender","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"10.1016\/j.semerg.2018.01.011_bib0310","first-page":"357","article-title":"Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population","volume":"36","author":"Piecoro","year":"2001","journal-title":"Health Serv Res."},{"key":"10.1016\/j.semerg.2018.01.011_bib0315","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.arbres.2009.04.006","article-title":"Coste econ\u00f3mico del paciente asm\u00e1tico en Espa\u00f1a (estudio AsmaCost)","volume":"45","author":"Mart\u00ednez-Morag\u00f3n","year":"2009","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.semerg.2018.01.011_bib0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.semerg.2016.05.008","article-title":"Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease","volume":"43","author":"Sicras","year":"2017","journal-title":"Semergen."},{"key":"10.1016\/j.semerg.2018.01.011_bib0325","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12913-016-1482-7","article-title":"The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries","volume":"16","author":"Lewis","year":"2016","journal-title":"BMC Health Serv Res."},{"key":"10.1016\/j.semerg.2018.01.011_bib0330","first-page":"CD012226","article-title":"Interventions to improve adherence to inhaled steroids for asthma","volume":"4","author":"Normansell","year":"2017","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359318300546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359318300546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T12:44:24Z","timestamp":1539348264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359318300546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1138359318300546"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2018.01.011","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistencia al tratamiento y uso de recursos con corticosteroides y agonistas \u03b2-adren\u00e9rgicos de larga duraci\u00f3n inhalados a dosis fijas para el tratamiento del asma: estudio retrospectivo de base poblacional","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}